Myra W. Popejoy

856 total citations
20 papers, 620 citations indexed

About

Myra W. Popejoy is a scholar working on Pharmacology, Epidemiology and Molecular Medicine. According to data from OpenAlex, Myra W. Popejoy has authored 20 papers receiving a total of 620 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pharmacology, 11 papers in Epidemiology and 7 papers in Molecular Medicine. Recurrent topics in Myra W. Popejoy's work include Antibiotics Pharmacokinetics and Efficacy (13 papers), Urinary Tract Infections Management (8 papers) and Antibiotic Resistance in Bacteria (7 papers). Myra W. Popejoy is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (13 papers), Urinary Tract Infections Management (8 papers) and Antibiotic Resistance in Bacteria (7 papers). Myra W. Popejoy collaborates with scholars based in United States, Greece and Japan. Myra W. Popejoy's co-authors include Benjamin Miller, Ellie Hershberger, Judith N. Steenbergen, Guojun Yuan, Christian Eckmann, Sylva H. Collins, Joseph S. Solomkin, Ian R. Friedland, Philip S. Barie and Minjung Yoon and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Myra W. Popejoy

18 papers receiving 613 citations

Peers

Countries citing papers authored by Myra W. Popejoy

Since Specialization

Citations

This map shows the geographic impact of Myra W. Popejoy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Myra W. Popejoy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Myra W. Popejoy more than expected).

Fields of papers citing papers by Myra W. Popejoy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Myra W. Popejoy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Myra W. Popejoy. The network helps show where Myra W. Popejoy may publish in the future.

Co-authorship network of co-authors of Myra W. Popejoy

This figure shows the co-authorship network connecting the top 25 collaborators of Myra W. Popejoy. A scholar is included among the top collaborators of Myra W. Popejoy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Myra W. Popejoy. Myra W. Popejoy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Vilastobart (XTX101), a tumor-activated, Fc-enhanced anti–CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with MSS CRC. 2025 ·Journal of Clinical Oncology ·Marwan Fakih, Nicholas C. DeVito, Aparna R. Parikh, Tanios Bekaii‐Saab, Hao Xie, (unknown), Alexander I. Spira, Jeremy Jones, Cesar A. Perez, (unknown), Alberto Bessudo, (unknown), (unknown), (unknown), Scott A. McConnell, Myra W. Popejoy, Bruce J. Dezube, Diwakar Davar, J. Randolph Hecht	0
2	A phase 3 study to evaluate efficacy and safety of VYD222, an IgG1 monoclonal antibody for prevention of COVID-19 (CANOPY): Subset analysis of participants with significant immune compromise in the setting of solid tumor or hematologic malignancies. 2024 ·Journal of Clinical Oncology ·Myra W. Popejoy, (unknown), (unknown), Kristin Narayan, (unknown), Deepali Gupta, (unknown), (unknown), Anna Holmes	0
3	Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial 2023 ·The Pediatric Infectious Disease Journal ·Emmanuel Roilides, Negar Ashouri, John S. Bradley, Matthew G. Johnson, (unknown), (unknown), Jennifer A. Huntington, Myra W. Popejoy, Mekki Bensaci, Carisa De Anda, Elizabeth G. Rhee, Christopher Bruno	19
4	Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection 2023 ·The Pediatric Infectious Disease Journal ·(unknown), Jason G. Newland, (unknown), (unknown), (unknown), Jennifer A. Huntington, Mekki Bensaci, Myra W. Popejoy, Matthew G. Johnson, Carisa De Anda, Elizabeth G. Rhee, Christopher Bruno	11
5	1143. Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonatal and Pediatric Participants With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized, Clinical Trial 2021 ·Open Forum Infectious Diseases ·Emmanuel Roilides, Negar Ashouri, John S. Bradley, Matthew G. Johnson, (unknown), (unknown), Jennifer A. Huntington, Myra W. Popejoy, Mekki Bensaci, (unknown), Elizabeth G. Rhee, Christopher Bruno	1
6	1154. Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-abdominal Infection: A Phase 2, Randomized Clinical Trial 2021 ·Open Forum Infectious Diseases ·(unknown), Jason G. Newland, (unknown), (unknown), (unknown), Jennifer A. Huntington, Mekki Bensaci, Myra W. Popejoy, Matthew G. Johnson, (unknown), Elizabeth G. Rhee, Christopher Bruno	3
7	A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia 2021 ·Clinical Infectious Diseases ·Richard G. Wunderink, Antoine Roquilly, Martin A. Croce, Daniel González, Satoshi Fujimi, Joan R. Butterton, (unknown), Myra W. Popejoy, (unknown), Carisa De Anda	32
8	Daptomycin for Pediatric Gram-Positive Acute Hematogenous Osteomyelitis 2020 ·The Pediatric Infectious Disease Journal ·John S. Bradley, Antonio Arrieta, (unknown), Myra W. Popejoy, Anjana Grandhi, Paula M. Bokesch, Ellie Hershberger, Marcus Dörr, Christopher M. Tan, Yoshihiko Murata, (unknown), Mekki Bensaci	14
9	2841. A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate (TZD) and Linezolid (LZD) for Treatment of Ventilated Gram-Positive (G+) Nosocomial Pneumonia 2019 ·Open Forum Infectious Diseases ·Richard G. Wunderink, Antoine Roquilly, Martin A. Croce, Daniel González, Satoshi Fujimi, Joan R. Butterton, (unknown), Myra W. Popejoy, (unknown), (unknown)	2
10	Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia 2018 ·The Pediatric Infectious Disease Journal ·Antonio Arrieta, John S. Bradley, Myra W. Popejoy, Mekki Bensaci, Anjana Grandhi, Paula M. Bokesch, Chad Glasser, Lihong Du, Hernando Patino, Nicholas A. Kartsonis	29
11	Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam 2017 ·BMC Infectious Diseases ·Myra W. Popejoy, Jianmin Long, Jennifer A. Huntington	16
12	Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae : a pooled analysis of Phase 3 clinical trials 2016 ·Journal of Antimicrobial Chemotherapy ·Myra W. Popejoy, David L. Paterson, Daniel Cloutier, Jennifer A. Huntington, Benjamin Miller, Caleb Bliss, Judith N. Steenbergen, Ellie Hershberger, Obiamiwe Umeh, Keith S. Kaye	95
13	Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam 2016 ·Journal of Antimicrobial Chemotherapy ·Ravina Kullar, Florian Wagenlehner, Myra W. Popejoy, Jianmin Long, Brian Yu, Ellie J. C. Goldstein	20
14	PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease 2016 ·Infectious Diseases and Therapy ·Alan Xiao, Luzelena Caro, Myra W. Popejoy, Jennifer A. Huntington, Ravina Kullar	32
15	Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study 2016 ·Antimicrobial Agents and Chemotherapy ·Benjamin Miller, Myra W. Popejoy, Ellie Hershberger, Judith N. Steenbergen, John C. Alverdy	29
16	Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI) 2015 ·Clinical Infectious Diseases ·Joseph S. Solomkin, Ellie Hershberger, Benjamin Miller, Myra W. Popejoy, Ian R. Friedland, Judith N. Steenbergen, Minjung Yoon, Sylva H. Collins, Guojun Yuan, Philip S. Barie, Christian Eckmann	311
17	Clinical Outcomes of Ceftolozane/Tazobactam Treatment of Piperacillin/Tazobactam and Ceftazidime Non-Susceptible Pathogens From Two Phase 3 Trials and Associated in Vitro Activity 2015 ·Open Forum Infectious Diseases ·Myra W. Popejoy, Eliana S. Armstrong, Benjamin Miller, (unknown), Patricia Bernardo, Judith N. Steenbergen, David J. Farrell, Ellie Hershberger	1
18	Outcomes of Ceftolozane/Tazobactam (C/T) in Patients With Moderate Renal Impairment in Two Phase 3 Trials for the Treatment of Complicated Intra-abdominal Infection (cIAI) and Complicated Urinary Tract Infection (cUTI) 2015 ·Open Forum Infectious Diseases ·(unknown), Myra W. Popejoy, Benjamin Miller	3
19	260Ceftolozane/Tazobactam for the Treatment of cUTI and cIAI Caused by ESBL-producing Enterobacteriaceae 2014 ·Open Forum Infectious Diseases ·Myra W. Popejoy, Daniel Cloutier, (unknown), Judith N. Steenbergen, Ellie Hershberger, Obiamiwe Umeh, Benjamin Miller, Keith S. Kaye	1
20	251Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Phase 3 Ceftolozane/Tazobactam Study 2014 ·Open Forum Infectious Diseases ·Benjamin Miller, Myra W. Popejoy, Ellie Hershberger, Judith N. Steenbergen, (unknown), Yuan Gao, (unknown), Ian R. Friedland, John Alverdy	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact